Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.3.23 (
GAS
)
957
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Streptococcus dysgalactiae subsp. equisimilis (group G streptococci; GGS) cause disease in humans but are often regarded as commensals in comparison with Streptococcus pyogenes (group A streptococci;
GAS
). The current study investigated the degree and kinetics of the innate immune response elicited by the two species. This was assessed as expression of the chemokine MIG/CXCL9 and bacterial susceptibility to its bactericidal effect. No significant difference in MIG/CXCL9 expression from THP-1 or Detroit 562 cells was observed when comparing whole GGS or
GAS
as stimuli. The study demonstrates that protein FOG was released from the bacterial surface directly and by
neutrophil elastase
. Expression of MIG/CXCL9 following stimulation with soluble M proteins of the two species (the recently described protein FOG of GGS and protein M1 of
GAS
) was reduced for protein FOG in both the monocytic and the epithelial cell line. When the antibacterial effects of MIG/CXCL9 were examined in conditions of increased ionic strength, MIG/CXCL9 killed
GAS
more efficiently than GGS. Also in the absence of MIG/CXCL9, GGS were more tolerant to increased salt concentrations than
GAS
. In summary, both GGS and
GAS
evoke MIG/CXCL9 expression but they differ in susceptibility to its antibacterial effects. This may in part explain the success of GGS as a commensal and its potential as a pathogen.
...
PMID:Protein FOG is a moderate inducer of MIG/CXCL9, and group G streptococci are more tolerant than group A streptococci to this chemokine's antibacterial effect. 1797 89